Avenue Therapeutics is a specialty pharmaceutical company developing novel therapies for neurologic diseases and acute pain. They are advancing a pipeline of first-in-class and best-in-class programs, including treatments for epilepsy, anxiety, spinal and bulbar muscular atrophy, and post-operative pain.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients suffering from neurologic diseases often face limitations with existing treatment options, leading to significant unmet medical needs. The development of novel therapies targeting these complex conditions is crucial for improving patient outcomes.
Solution
Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for neurologic diseases. The company's strategy centers on advancing a diverse pipeline of first-in-class and best-in-class programs designed to address significant unmet patient needs. By leveraging targeted therapeutic approaches, Avenue aims to improve the standard of care and transform patient outcomes in this challenging therapeutic landscape.
Target Audience
The primary target audience includes patients and healthcare providers involved in the treatment of neurologic diseases, such as epilepsy, anxiety disorders, and spinal and bulbar muscular atrophy, as well as those managing acute post-operative pain.
Features
- **BAER-101:** A positive allosteric modulator (PAM) of α2,3 subunit-containing GABA A receptors, developed for epilepsy and acute anxiety. It targets specific GABA A receptor subtypes to potentially minimize benzodiazepine-associated adverse effects like tolerance, dependence, and sedation. Preclinical studies in the GAERS model of absence epilepsy demonstrated full suppression of seizure activity.
- **AJ201:** A potential best-in-class asset for spinal and bulbar muscular atrophy (SBMA). It is being evaluated in a Phase 1b/2a clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, including changes in mutant AR protein levels and Nrf2-activated gene expression. Exploratory objectives include assessing changes in muscle composition via MRI.
- **IV Tramadol:** An intravenous formulation of tramadol being developed for acute post-operative pain management in medically supervised settings. It utilizes a dual mechanism of action, combining opioid agonism with inhibition of norepinephrine and serotonin reuptake, aiming to provide pain relief with reduced abuse potential. Phase 3 studies have demonstrated safety and efficacy, and a final safety study protocol has been agreed upon with the FDA.